



## Retigabine – positive results in Phase III study

Results presented at the Annual Meeting of the American Epilepsy Society in Seattle December 6 demonstrate that Retigabine as an adjunctive treatment resulted in statistically significant reduction of seizures and that the response dose-dependent. The study (RESTORE 2) is a randomized, double-blind, placebo-controlled Phase III study (600mg and 900 mg) with the aim to compare Retigabine versus placebo in patients on antiepileptic drug therapy.

Retigabine comprises a new way of affecting potassium channels in the central nervous system. It has been documented to treat epilepsy and has a different mechanism of action compared to current antiepileptic therapies. According to GlaxoSmithKline and Valeant, the registration application for the first indication, epilepsy, is expected to be submitted early 2009 in both the U.S. and in Europe.

---

For more information contact:

Anders Larnholt, VP Investor Relations

Phone. +46 709 458 878

---

**MEDA AB (publ)** is a leading international specialty pharma company. The company specialises in marketing and pharmaceutical development in late clinical stage. Acquisitions and long-term partnerships are fundamental factors that drive the company's strategy. Meda is represented by its own organisations in about 40 countries. Meda's products are sold in 120 countries worldwide. The Meda share is listed under Large Cap on the OMX Nordic Stock Exchange. Find out more, visit [www.meda.se](http://www.meda.se).